Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Rhea-AI Summary
Immunovia (IMMNOV: Nasdaq Stockholm) presented results from its model development study for a next-generation pancreatic cancer detection test at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer. The study, involving 623 patient samples, demonstrated the test's superior performance with 85% sensitivity and 98% specificity. Notably, the test's sensitivity surpassed that of CA19-9, a common pancreatic cancer biomarker, by 20 percentage points.
The presentation detailed the biomarker selection process, algorithm construction, and test performance. Immunovia's VP of Clinical and Medical Affairs, Norma Palma PhD, emphasized the importance of scientific review and data dissemination for driving adoption of the test, which is slated for launch next year.
Positive
- Immunovia's new pancreatic cancer test showed 85% sensitivity and 98% specificity in a 623-patient sample study
- The test's sensitivity exceeded that of CA19-9, a common pancreatic cancer biomarker, by 20 percentage points
- Presentation at a prestigious AACR conference may increase visibility and credibility for Immunovia's technology
- The company estimates a potential market of 1.8 million high-risk individuals in the USA who could benefit from annual testing
Negative
- The test is still in development and not yet commercially available
- Actual market adoption and revenue generation remain uncertain
Insights
The presentation of Immunovia's model development study results at the AACR conference is a significant step forward in pancreatic cancer diagnostics. The 85% sensitivity and 98% specificity of their next-generation test are impressive figures, especially for early-stage detection. This 20 percentage point improvement over CA19-9 could be a game-changer in early diagnosis.
However, it's important to note that these results are from a controlled study with 623 samples. Real-world performance may vary. The true test will be in prospective clinical trials and eventual clinical implementation. The company's focus on rigorous scientific review is commendable, but investors should watch for peer-reviewed publications and independent validation of these results.
Immunovia's focus on the US market is strategically sound, given its estimate of 1.8 million high-risk individuals who could benefit from annual testing. This represents a substantial market opportunity. However, market penetration will depend on factors like cost-effectiveness, insurance coverage and physician adoption.
The company's collaboration with healthcare providers and patient advocacy groups is important for market acceptance. Investors should monitor progress in these partnerships and any advancements in reimbursement discussions. While the potential is significant, the path from promising study results to commercial success in diagnostics can be long and uncertain, especially in a field as challenging as pancreatic cancer detection.
Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test's performance and stability. In the study of 623 patient samples, the test demonstrated superior performance, with sensitivity of
The conference is being hosted by the American Association for Cancer Research (AACR) in
"We are grateful to have been selected by the AACR reviewers to present the model-development-study results at this inspiring conference of pancreatic cancer advances. Rigorous scientific review and dissemination of our data will be critical for driving adoption of our next-generation test following its launch next year," said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
+46 70 911 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-presents-data-from-model-development-study-at-2024-aacr-advances-in-pancreatic-cancer-medical-conference-302249247.html
SOURCE Immunovia AB
FAQ
What were the key results of Immunovia's pancreatic cancer test study presented at the 2024 AACR conference?
When is Immunovia (IMMNOV) planning to launch its new pancreatic cancer detection test?
How large is the potential market for Immunovia's pancreatic cancer test in the USA?
What is the focus of Immunovia's (IMMNOV) diagnostic technology?
